Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Purchased: 1,150,000 Ordinary shares of 25 pence each.
- Purchase Date: June 3, 2011.
- Price Range: Highest price paid was 1,296.5 pence per share; lowest price paid was 1,281 pence per share.
- Treasury Shares Held: 499,174,284 shares (representing 8.82% of total issued share capital and 9.68% of total voting rights).
- Shares in Issue: 5,157,781,781 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 1,150,000 repurchased shares. Consequently, the Company's Treasury holdings increased to 499,174,284 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,157,781,781) for calculating disclosure thresholds under the Financial Services Authority's rules.
- Confirm the updated Treasury share count (499,174,284) and its impact on voting rights (9.68%).
- Note that the repurchased shares were cancelled rather than held for reissue.